We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Mallinckrodt on Wednesday confirmed that it received a complete response letter from the FDA regarding a filing seeking approval of stannsoporfin for use in newborns at risk of jaundice.